Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27712066 | 0.98 | NPC1 (0.51) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL6466331 | 0.86 | CHRM5 (0.44) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| Hydrochloric Acid SCHEMBL27810068 | 0.84 | CHRM5 (0.43) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL12157404 | 0.82 | ALDH1A1 (0.53) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL742714 | 0.82 | ALDH1A1 (0.50) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL4238576 | 0.82 | RXFP1 (0.60) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| Hydrochloric Acid SCHEMBL14895505 | 0.81 | RXFP1 (0.58) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL13211046 | 0.78 | ALDH1A1 (0.60) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL31119754 | 0.78 | IKBKB (0.56) | NPC1RAB9AKDM4EL3MBTL1HKDC1 | |
| SCHEMBL22955425 | 0.78 | RIPK1 (0.62) | NPC1RAB9AKDM4EL3MBTL1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111505071-B | Integrated microelectrode sensor for simultaneous detection of pH and AA and preparation method and application thereof | 商丘师范学院 | 2022-06-10 | — | — | CN | claimed |
| CN-102206216-B | Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC | 2014-11-12 | — | — | CN | claimed |
| EP-2142610-B1 | DYE-BASED INK FORMULATIONS | HEWLETT PACKARD DEVELOPMENT CO (US) | 2014-03-12 | — | — | EP | claimed |
| US-8562121-B2 | Black ink-jet inks with reduced lightness and haze | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2013-10-22 | — | — | US | claimed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| CN-101663365-B | Dye-based black ink formulations and inkjet ink sets | SHANGHAI HEWLETT PACKARD CO LTD | 2012-09-05 | — | — | CN | claimed |
| EP-2220168-B1 | BLACK INK-JET INKS WITH REDUCED LIGHTNESS AND HAZE | HEWLETT PACKARD DEVELOPMENT CO (US) | 2012-07-25 | — | — | EP | claimed |
| CN-102206216-A | Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC | 2011-10-05 | — | — | CN | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110043577-A1 | Black Ink-jet Inks With Reduced Lightness And Haze | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2011-02-24 | — | — | US | claimed |
| EP-2097414-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2009070176-A1 | BLACK INK-JET INKS WITH REDUCED LIGHTNESS AND HAZE | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2009-06-04 | — | — | WO | claimed |
| WO-2008131393-A2 | DYE-BASED BLACK INK FORMULATIONS AND INK-JET INK SETS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2008-10-30 | — | — | WO | claimed |
| WO-2008131396-A2 | DYE-BASED INK FORMULATIONS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080257207-A1 | Dye-based ink formulations | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2008-10-23 | — | — | US | claimed |
| US-20080257206-A1 | Dye-based black ink formulations and ink-jet ink sets | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2008-10-23 | — | — | US | claimed |
| WO-2008124524-A2 | ARYL SULFONAMIDE COMPOUNDS AS MODULATORS OF THE CCK2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-16 | — | — | WO | claimed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | claimed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2008026046-A1 | MORPHOLINE D3 DOPAMINE ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-03-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NPC1 2367/4885RAB9A 1597/4885KDM4E 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.